Top Markets
Coin of the day
HLS Therapeutics Inc. HLS Therapeutics Inc.

HLS Therapeutics Inc.

HLS
Ранг среди акций #22602
HLS Therapeutics Inc. operates as a specialized pharmaceutical firm,... HLS Therapeutics Inc. operates as a specialized pharmaceutical firm, concentrating on the acquisition and commercialization of medicinal products, primarily within the niche central nervous system (CNS) and cardiovascular (CV) sectors. Its reach extends across Canada, the United States, and international markets. The company's core product lineup includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsule formulation; and PERSERIS, an injectable risperidone product for treating schizophrenia. Additionally, HLS offers MyCare psychiatry laboratory assays and MyCare Insite tests for point-of-care therapeutic drug-level monitoring. Furthermore, the company possesses U.S. marketing privileges for Absorica, a commercial-stage dermatology solution, and Canadian rights for Trinomia, a cardiovascular therapeutic. It also manages a portfolio of royalty interests from four distinct healthcare products. Founded in 2018, HLS Therapeutics Inc. is based in Etobicoke, Canada.
Цена акции
$2.75
Последняя синхронизация: 2026-08-21
Рыночная капитализация
$86.08M
Изменение (1 день)
-3.85%
Изменение (1 год)
-27.06%
Страна
CA
Торговля HLS Therapeutics Inc. (HLS)

Категория

Коэффициент P/B для HLS Therapeutics Inc. (HLS)
Коэффициент P/B на 2026 TTM: 0
Согласно последним финансовым отчетам и цене акций HLS Therapeutics Inc., текущий коэффициент P/B (TTM) составляет 0. В конце 2026 он составлял 0.
История P/B для HLS Therapeutics Inc. с 2026 по 2026
Коэффициент P/B в конце каждого года
Год P/B Изменить
Недостаточно данных для указанных дат.
Коэффициент P/B для аналогичных компаний или конкурентов